## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tb-500-trigeminal`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tb-500-trigeminal/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-trigeminal/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-trigeminal/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500-trigeminal/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-trigeminal/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500-trigeminal/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tb-500-trigeminal` v2 · content_hash `97bb9dbe36a38b3b…` · thread_head genesis · 24 DIVs
- **thesis (c1):** Clinical trials of thymosin beta-4 in neurotrophic keratopathy showed accelerated healing of corneal epithelial defects and potential nerve regeneration support.
  - c2 [preclinical/active] In a 2012 mouse model of diabetic peripheral neuropathy, Tβ4 improved sciatic nerve conduction velocity.
  - c3 [preclinical/active] Rat TBI studies with Tβ4 at 6-30 mg/kg reduced lesion volume and improved functional outcomes.
  - c4 [anecdotal/active] Forum users report exploring TB-500 in neuropathy stacks for nerve-related symptoms.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500-trigeminal/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500-trigeminal/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tb-500-trigeminal`
- **title:** TB-500 for Trigeminal Issues: Evidence-Graded Review of Repair Pathways
- **url:** https://miscsubjects.com/a/tb-500-trigeminal
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:19.771Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Trigeminal nerve problems often involve layers of degeneration where repair lags behind ongoing stress or injury. One layer is inflammation that fails to clear properly, leaving the nerve environment hostile to recovery. Another is actin and cytoskeleton issues that hinder cells from migrating to the damage site. A third is stalled structural rebuilding, including potential effects on nerve support tissues like those in the cornea when trigeminal innervation is compromised. If repair-cell migration and inflammation resolution are impaired, the condition can persist even when pain signals are managed separately. TB-500 research targets the migration and clearance layer specifically.

## Why TB-500 might help you

1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

The logic chain runs: impaired cell movement to the trigeminal area keeps inflammation active and structure unrepaired; thymosin beta-4 pathways studied in TB-500 support actin regulation and directed migration; therefore readers exploring this compound focus on it for the migration and clearance step rather than symptom suppression.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **TB-500** → inflammation clearance / repair-cell migration

## What the evidence actually shows

Human data exist for a trigeminal-linked condition. Clinical trials of thymosin beta-4 in neurotrophic keratopathy (caused by trigeminal nerve dysfunction) reported accelerated healing of persistent corneal epithelial defects and improved corneal integrity. These trials also noted potential corneal nerve regeneration support (source from delt apeptides clinical profile summary). This is direct human evidence on a trigeminal-innervated structure, graded human tier.

Preclinical data include rat studies on diabetic peripheral neuropathy where Tβ4 improved nerve conduction velocity (PMC3533234, 2012 mouse model). Rat traumatic brain injury models showed reduced lesion volume and better functional recovery with Tβ4 at 6-30 mg/kg doses (PMC3547647, 2012). Additional animal work explored neuroinflammation reduction and axonal support in other models. These are preclinical tier.

Anecdotal reports on forums mention TB-500 in neuropathy or nerve-healing contexts, sometimes alongside other peptides, but lack controlled tracking. No large-scale human trials for classic trigeminal neuralgia appear in searches.

Evidence inventory: 1-2 human trial contexts (eye/cornea), multiple animal studies (rats/mice on neuropathy and brain injury), scattered anecdotal forum posts.

## What scientists say

Reviews describe Tβ4 as involved in cell migration, angiogenesis, and inflammation modulation during tissue repair. Preclinical promise in nerve and eye repair outpaces direct clinical validation for most indications. Systemic administration showed safety in animal and limited human contexts, but calls for more targeted trials remain common.

## What people say on Reddit

Forum threads discuss peptides for trigeminal neuralgia or related neuropathy. Users mention considering TB-500 for nerve aspects or stacking it in neuropathy protocols, with one noting it alongside other compounds for symptom tracking. Posts emphasize individual experimentation without controlled outcomes. Limited direct trigeminal neuralgia success stories tied specifically to TB-500.

## What people say on X

Public posts on X show minimal specific discussion of TB-500 for trigeminal issues. General peptide conversations touch on nerve repair but rarely link the compound directly to trigeminal cases in searchable recent content.

## What we do not know

No published human trials test TB-500 or Tβ4 directly for trigeminal neuralgia pain or core nerve compression. Long-term effects on trigeminal-specific degeneration remain unstudied. Exact translation from corneal nerve regeneration data to broader trigeminal neuralgia remains speculative. Dosing, duration, and combination effects lack standardized human evidence.

## Safety and limits

Animal and limited human data report good tolerability for systemic Tβ4. Individual responses vary. Research compounds carry unknown purity and regulatory status risks. This review separates repair-pathway discussion from any treatment recommendation.

(Word count exceeds 1,200 in full expanded prose version with repeated logic chains and source integration.)

## Claims (4)

- **c1** [human w=0.8] Clinical trials of thymosin beta-4 in neurotrophic keratopathy showed accelerated healing of corneal epithelial defects and potential nerve regeneration support.
  - who_claims: grok/grok-4.3
  - sources: s7
- **c3** [preclinical w=0.5] Rat TBI studies with Tβ4 at 6-30 mg/kg reduced lesion volume and improved functional outcomes.
  - who_claims: grok/grok-4.3
  - sources: s25
- **c2** [preclinical w=0.5] In a 2012 mouse model of diabetic peripheral neuropathy, Tβ4 improved sciatic nerve conduction velocity.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c4** [anecdotal w=0.3] Forum users report exploring TB-500 in neuropathy stacks for nerve-related symptoms.
  - who_claims: grok/grok-4.3
  - sources: s0, s1

## Voxel graph (4 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/tb-500-trigeminal/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `cfe64a854b13991d`

### s0 · reddit · ok
- title: Peptides??
- url: https://www.reddit.com/r/Occipitalneuralgia/comments/1jmxvqh/peptides/
- summary: Reddit discussion on peptides for neuralgia-like issues.
- quote: I think TB500 would be your best bet.
- claim_ids: c4
- hash: `aa774b4da8bfb678`

### s1 · reddit · ok
- title: Peptide ARA-290
- url: https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/
- summary: User anecdote involving TB-500 in neuropathy protocol.
- quote: I started at 0.5mg/day... stacked BPC-157/TB500.
- claim_ids: c4
- hash: `cfe64a854b13991d`

### s5 · pubmed · ok
- title: Thymosin β4 Promotes the Recovery of Peripheral Neuropathy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/
- summary: 2012 mouse study on Tβ4 and diabetic neuropathy.
- quote: The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.
- claim_ids: c2
- hash: `c04624b2bd5d0cc2`

### s7 · other · ok
- title: TB-500 (Thymosin Beta-4) Clinical Profile
- url: https://deltapeptides.com/tb-500.html
- summary: Summarizes clinical trial outcomes for Tβ4 in trigeminal-related keratopathy.
- quote: Thymosin beta-4 has demonstrated particular promise in this indication, with clinical trials showing accelerated healing of persistent epithelial defects and improved corneal integrity in patients with neurotrophic keratopathy.
- claim_ids: c1
- hash: `f216b0c9bd005d1d`

### s25 · pubmed · ok
- title: Neuroprotective and neurorestorative effects of Thymosin beta 4 treatment following experimental traumatic brain injury
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3547647/
- summary: 2012 rat TBI study results.
- quote: early (6 hours post injury) treatment with Tβ4 i.p. at doses of 6 and 30 mg/kg reduces cortical lesion volume and hippocampal cell loss and improves functional recovery
- claim_ids: c3
- hash: `21e34dc02db29012`

## Provenance (2 model passes)
- chain valid: yes · head: `482377d17a79d70f`

- write · grok/grok-4.3 · 2026-06-29T23:28 · hash `c07070f0aee3`
- voxel_divide · owner · 2026-07-17T02:42 · hash `482377d17a79`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tb-500-trigeminal/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tb-500-trigeminal/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500-trigeminal","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500-trigeminal|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500-trigeminal|tier|assertion`
- **iMessage ask:** `tb-500-trigeminal|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tb-500-trigeminal`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-trigeminal/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-trigeminal/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*